Recursion Pharmaceuticals Inc. Class A (RXRX)
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RXRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.53B
- EPS (TTM)
- -$0.86
- Dividend yield
- None
- 52-week range
- 2.44 – 5.24
- Day range
- 2.44 – 2.76
- Volume / Avg
- 29.80M / 24.47M
- Beta
- —
- Shares outstanding
- 622.76M
52-week range
RXRX stock today
On Nov 20, RXRX ended the session at $2.45, shedding $0.27 (9.93%), versus the S&P 500's 3.70% decline. At this level, RXRX sits near the bottom of its 52-week range of $2.44 to $5.24: 53.2% below the high, set on Jan 22, 2026 and 0.4% above the low. RXRX is down 40.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.2%.
Recursion Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.86), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Recursion Pharmaceuticals
Company profileRecursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Najat Khan Ph.D.
- Headquarters
- Salt Lake City, UT
- Employees
- 600
- IPO year
- 2021
- Website
- recursion.com
Financial highlights
Full financialsIn fiscal 2025, Recursion Pharmaceuticals generated $74.7 million in revenue, up 26.9% from fiscal 2024, its 6th consecutive year of revenue growth. Recursion Pharmaceuticals reported a net loss of $644.8 million, compared with a loss of $463.7 million a year earlier. Gross margin was 5.0% (down from 23.1%) and operating margin -867.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $74.68M | $58.84M | $44.58M | $39.84M | $10.18M |
| Growth | +26.92% | +32.00% | +11.88% | +291.46% | +156.89% |
| Net income | $-644.76M | $-463.66M | $-328.07M | $-239.48M | $-186.48M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$6.77+176.33%
- Strong buy 2
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.22 vs $-0.24
- Surprise
- +8.33%
RXRX news
All RXRX news- Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 DesignNasdaqRXRX, SUN
- Why Recursion Pharmaceuticals Stock Is Up TodayNasdaqRXRX, MKC.V
- Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock UpNasdaqRXRX, LEN.B
- Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisGlobeNewswire
- Recursion to Participate in Upcoming Investor ConferencesGlobeNewswire
- Recursion (RXRX) Q3 2026 Earnings Call TranscriptNasdaq
- Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone RevenuesNasdaqRXRX, SNY, IOVA, AMRX
- Recursion Pharma Q3 Net Loss Narrows, Reports Positive REC-4881 Data; Advances PipelineNasdaqRXRX, LEN.B
Recursion Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs RXRX |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs RXRX |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs RXRX |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs RXRX |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs RXRX |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs RXRX |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs RXRX |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs RXRX |
Indexes, lists and sector
Recursion Pharmaceuticals stock FAQ
What is Recursion Pharmaceuticals's stock price today?
RXRX last traded at $2.45 as of Nov 20, 4:00 PM EST, down 9.93% on the day. Prices are delayed at least 15 minutes.
Who is Recursion Pharmaceuticals's CEO?
Dr. Najat Khan Ph.D. is the chief executive officer of Recursion Pharmaceuticals Inc. Class A, which has about 600 employees.
What is the RXRX 52-week high?
The 52-week high for RXRX is $5.24 and the 52-week low is $2.44. The stock is currently 53.2% below its high.